VASTox gaint Duchenne Muscular Dystrophy patent
VASTox plc announced that the US Patent Office has granted a patent (US Application No.10/089,928/Utrophin Gene Promoter) which provides additional protection to the Company's drug discovery programme in Duchenne muscular dystrophy (DMD).
The granting of this patent increases the value of VASTox's DMD programme as it further protects the Company's approach to finding new medicines to treat this fatal disease. This patent has also been filed in other territories including Europe and is in addition to an earlier DMD related patent that has already been granted in the US, Europe and Australia.
VASTox's scientific approach involves using small drug like molecules to increase the body's levels of a protein called utrophin to replace a very similar protein called dystrophin which is missing in DMD patients. The absence of dystrophin leads to severe muscle wasting and is ultimately fatal for all DMD sufferers.
In recent months, VASTox has sought to further strengthen the patent estate around its DMD programme through the filing of a significant number of patents which cover several classes of active compounds which have been identified during the development of the DMD programme.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
East German physicians prescribe significantly more high-priced biopharmaceutical medication than West German doctors - 127% higher revenues of pharmaceutical companies per physician and year in the area of former East Germany
Apeiron announces start of phase I trail with cellular anti cancer therapy
Tecan and the Monash Antibody Technologies Facility unveil custom monoclonal antibody production facility
Acacia Pharma starts clinical trial with APD515 for Xerostomia

Innovative therapeutic tools in the fight against cancer - Spin-off company of the University Medical Center Mainz starts operations and enters into joint venture with Indivumed
Cardio3 BioSciences Appoints Dr. Alexander Milstein as Vice President of Clinical Development
Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
MediGene Initiates Clinical Formulation Study of RhuDex for the Oral Treatment of Autoimmune Diseases
